Thermo Fisher (0R0H) AI Stock Analysis

Thermo Fisher

(LSE:0R0H)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Diversified recurring-revenue modelRevenue combines repeat-purchase consumables, service contracts and workflow products with instruments that generate downstream pull-through. This mix, spanning pharma, research, clinical and industrial customers, supports recurring demand and reduces reliance on any single end market.

Negative Factors

Meaningful leverageMeaningful debt and elevated leverage increase fixed financial obligations and reduce flexibility relative to a lightly levered balance sheet. They can constrain capital allocation and make the company more sensitive to slower growth, refinancing conditions or sustained interest expense.

Thermo Fisher (0R0H) vs. iShares MSCI United Kingdom ETF (EWC)

Market Cap: $257.71B
Dividend Yield: 0.27%
Average Volume (3M): 2,512
Price to Earnings (P/E): 36.7
Beta (1Y): 1.06
Revenue Growth: 8.27%
EPS Growth: 9.59%
Country: UK
Employees: 125,000
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Diagnostics & Research

Thermo Fisher Business Overview & Revenue Model

Company Description

Thermo Fisher Scientific Inc. is a global leader in scientific services, providing a comprehensive range of offerings that include life sciences solutions, advanced analytical instruments, specialized diagnostic products, and an extensive portfolio o...

Thermo Fisher Earnings Call Summary

Earnings Call Date:Oct 20, 2026(Q3-2026)|% Change Since:0.46%|Next Earnings Date:Feb 03, 2027

Earnings Call SentimentPositive

The call was strongly positive. Thermo Fisher delivered broad-based revenue, profit, margin, cash flow, and organic growth improvements; exceeded prior guidance; raised full-year revenue, EPS, and free cash flow guidance; and reported continued momentum in pharma, biotech, analytical instruments, AI, clinical research, and bioproduction. The main challenges were flat academic and government revenue, a decline in reported Specialty Diagnostics revenue, muted reagent demand, unfavorable mix, and some Pharma Services timing between the third and fourth quarters.

Positive Updates

Strong Third-Quarter Financial Performance

Revenue grew 9% year over year to $12.14 billion, adjusted operating income increased 15% to $2.97 billion, adjusted operating margin expanded by 120 basis points to 24.5%, and adjusted EPS grew 15% to $6.68. GAAP EPS was $4.64, up 9%.

Negative Updates

Academic and Government Revenue Was Flat

Revenue in the academic and government end market was flat during the quarter, although management noted good performance in chromatography and mass spectrometry and continued demand for high-end instrumentation.

Company Guidance

For 2026, guidance is revenue of $47.7 billion-$48.2 billion, representing 7%-8% reported revenue growth over 2025 and full-year organic revenue growth of 4%; adjusted earnings per share is $25.13-$25.43 per share, representing 10%-11% growth; fourth-quarter organic revenue growth is expected to be 4%, with a year over year revenue tailwind from foreign exchange of approximately $200 million for the year; guidance assumes 80 basis points of adjusted operating income margin expansion, approximately $650 million of net interest expense, an adjusted income tax rate of 11.5%, between $1.9 billion and $2 billion of net capital expenditures, free cash flow between $7 billion and $7.5 billion, $4 billion of share buybacks, approximately $700 million of capital returned through dividends, and a full-year average diluted share count between 371 million and 372 million shares.

Thermo Fisher Risk Analysis

Thermo Fisher disclosed 26 risk factors in its most recent earnings report. Thermo Fisher reported the most risks in the "Legal & Regulatory" category.

Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

0 New Risks

Thermo Fisher Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

GB:0R0H against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IDXX	80Outperform	$43.42B	38.71	71.96%	―	12.77%	18.22%
A	75Outperform	$49.30B	34.35	20.47%	0.58%	8.60%	19.07%
MTD	75Outperform	$33.56B	37.60	-1199.91%	―	6.91%	12.43%
DHR	73Outperform	$163.38B	37.95	8.18%	0.65%	5.52%	25.53%
WAT	57Neutral	$45.46B	115.10	1.88%	―	52.47%	-63.86%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

GB:0R0H and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
GB:0R0H	Thermo Fisher Scientific	693.58	132.91	23.71%
A	Agilent Technologies	174.87	31.26	21.77%
DHR	Danaher Corporation	232.23	19.74	9.29%
IDXX	Idexx Laboratories	551.21	-171.73	-23.75%
MTD	Mettler-toledo International	1674.81	267.93	19.04%
WAT	Waters Corp	462.72	117.13	33.89%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Thermo Fisher AI Stock Analysis